去纤苷用多久有效果？

(Also called defibrinated sodium) is an adenosine receptor agonist with multiple effects. It can reduce the expression of cell adhesion molecules on the surface of endothelial cells, thereby reducing the adhesion of leukocytes to vascular endothelial cells and reducing the inflammatory damage of endothelial cells. Today we will learn more about how long does defibrinoside take to be effective?

Defibrotide is currently recognized as the most promising new drug for the treatment of hepatic veno-occlusive disease (HOVD) after hematopoietic stem cell transplantation (HSCT). Based on its anticoagulant, fibrinolysis-promoting, and anti-inflammatory effects, its application in the treatment of HVOD after HSCT was explored. This study included 19 sHOVD patients. The dosage of defibrotide is 5~60mg/kg per day, intravenous infusion, and the median usage time is 15d (2-61d).

The results showed that 42% of patients achieved complete remission (CR), and the overall survival (os) rate 100 days after transplantation reached 32%, and patients could tolerate defibrotide well. Since then, multiple clinical trials have confirmed the effectiveness of defibrotide in the treatment of HVOD.

Hepatic venule occlusion causes edema and reduced blood flow in the liver due to blockage of some blood vessels in the liver. This condition can lead to the most severe liver damage. The drug is the first drug approved by the FDA for the treatment of severe hepatic venous occlusion, a rare and fatal liver disease.

The approval was based on a Phase 2 trial of 75 patients, a Phase 3 trial of 102 patients, and an expansion trial of an additional 351 patients. All patients in the trial were diagnosed with hepatic VOD and associated renal or pulmonary dysfunction after HSCT. In the phase 2 trial, 44% of patients survived 100 days after transplantation, compared with 38% in the phase 3 trial and 45% in the expanded trial, and the FDA noted in a report that the expected 100-day survival rate in patients with severe hepatic VOD who were not treated with defibrotide was 21%-31%.

Data on the safety of defibrotide (also called defibrotide sodium) are based on 176 patients. The most common adverse reactions include hypotension, diarrhea, vomiting, nausea, and epistaxis. The most common serious adverse reactions include hypotension and alveolar hemorrhage. The approval of defibrotide greatly meets the treatment needs of transplant patients suffering from such rare and fatal complications.

Defibrotide (also called defibrotide sodium) is not only used to prevent hepatic veno-occlusive disease (VOD), but can also be used to treat hepatic veno-occlusive disease (HVOD) and has good efficacy, and side effects such as nausea, hypotension, fever and severe bleeding are rare.

The above is the content of the effect of (also called fiber-removing sodium), I hope it can help you!

Recommended related hot articles: /newsDetail/84585.html